JOHNSON & Johnson said on Thursday (May 16) it would acquire Proteologix for US$850 million in cash, as it looks to gain access to the privately held company’s experimental atopic dermatitis treatments.
Source link
JOHNSON & Johnson said on Thursday (May 16) it would acquire Proteologix for US$850 million in cash, as it looks to gain access to the privately held company’s experimental atopic dermatitis treatments.
Source link
I am an editor for Ny Journals, focusing on business and entrepreneurship. I love uncovering emerging trends and crafting stories that inspire and inform readers about innovative ventures and industry insights.
The NY Journals pride themselves on assembling a proficient and dedicated team comprising seasoned journalists and editors. This collective commitment drives us to provide our esteemed readership with nothing short of the most comprehensive, accurate, and captivating news coverage available.
Transcending the bounds of New York City to encompass a broader scope, we ensure that our audience remains well-informed and engaged with the latest developments, both locally and beyond.
© 2025 The New York Journals. All Rights Reserved.